Assignee: Applied Research Systems ARS Holding N.V.

Location: Curacao, AN
No. of patents: 109

Number	Title	Issue Date
7317095	Mutant glycoproteins The inventors have designed novel FSH mutants with increased glycosylation and longer half-lives for use in inducing folliculogenesis in human patients. The use of a FSH mutant preparation of the invention permits the use of lower cumulative doses of FSH to achieve ...	01/08/2008
7317002	Site-specific preparation of polyethylene glycol-GRF conjugates A method is described for the site-specific preparation of hGRF-PEG conjugates containing one or more PEG units (per mole of hGRF) covalently bound to Lys12 and/or Lys21 and/or Nα, characterized in that the conjugation reaction betw...	01/08/2008
7276531	G-lactam derivatives as prostaglandin agonists A gamma-lactam diene of Formula I: which is particularly useful as a medicament for the treatment of various disorders such as asthma, hypertension, osteoporosis, sexual dysfunction and fertility disorders. ...	10/02/2007
7268210	PEG-LHRH analog conjugates PEG-LHRH analog conjugates, where a PEG moiety is covalently bound to a serine residue of a LHRH analog, and methods for producing these conjugates are provided in the present invention. Also provided are a pharmaceutical composition and a method for treating pathol...	09/11/2007
7258997	Methods of increasing protein expression levels The present invention relates to methods of increasing protein expression levels whereby at least one amino acid in a protein amino acid sequence is substituted for the amino acid, proline. Preferably, the substitution occurs within 15 amino acids, more preferably w...	08/21/2007
7256321	Intracellular modulators of apoptopic cell death pathways A DNA sequence encoding a glucocorticoid-induced leucine-zipper family related protein (GILR), isoforms, fragments or analogs thereof, said GILR, isoforms, fragments or analogs thereof capable of inhibiting apoptosis and stimulating lymphocyte activity, GILR protein...	08/14/2007
7235524	Medicaments for initiating ovulation The invention relates to medicaments for initiating ovulation comprising LH in an administrable form which ensures an increase in LH plasma levels for a period of some 40 to 60 hours. ...	06/26/2007
7223732	Compound B as an angiogenic agent in combination with human growth factors Compound B is shown to promote angiogenesis, specifically, budding of capillaries. The combination of Compound B and with human growth factor, such as bFGF, shows synergistic angiogenetic effects. ...	05/29/2007
7217687	Use of osteopontin for the treatment and/or prevention of neurologic diseases The invention relates to the use of osteopontin, or of an agonist of osteopontin activity, for treatment or prevention of a neurologic diseases. ...	05/15/2007
7211601	Pharmaceutically active pyrrolidine derivatives The present invention is related to pyrrolidine derivatives of formula (I). Said compounds are preferably for use as pharmaceutically active compounds. Specifically, pyrrolidine derivatives of formula (I) are use...	05/01/2007
7189754	Pyrrolidine ester derivatives with oxytocin modulating activity The present invention is related to the use of pyrrolidine esters of formula (I) for the treatment and/or prevention of premature labor, premature birth and dysmenorrhea. In particular, the present invention is related to the use of pyrrolidine esters of formula (I)...	03/13/2007
7183251	hCG therapy for the treatment of breast cancer This invention relates to the field of cancer therapy. More particularly, the invention relates to the treatment of mammary tumor, clinically manifest mammary tumor (breast cancer) and metastatic mammary tumor by administration of human Chorionic Gonadotropin (hCG)....	02/27/2007
7151083	Luteinizing hormone and follicle stimulating hormone for use in inducing folliculogenesis The present invention relates to the use of gonadotrophins in the induction of folliculogenesis in anovulatory women. In particular, it relates to the use of LH (or an equivalent dosage of hCG) in the production of a medicament for inducing folliculogenesis in anovu...	12/19/2006
7115639	Pyrrolidine oxadiazole- and thiadiazole oxime derivatives being oxytocin receptor antagonists The present invention is related to pyrrolidine oxadiazole and thiadiazole derivatives for use as pharmaceutically active compounds, as well as pharmaceutical formulations containing such pyrrolidine oxadiazole derivatives. Said pyrrolidine derivatives are useful in...	10/03/2006
7115754	Pyrrolidine derivatives as oxytocin antagonists The present invention relates to novel pyrrolidine derivative of formula (I), its geometrical isomers, its optically active forms as enantiomers, diastereomers, mixtures of these and its racemate forms, as well as salts thereof, wherein R1 is selected fro...	10/03/2006
7101665	Method for the identification of gene transcripts with improved efficiency in the treatment of errors A method for identification of gene transcripts comprises the steps of: generating a set of raw sequences by sequencing of biological material; isolating ditags from the set of raw sequences; isolating tags from the ditags; determining abundance of the tags; and ide...	09/05/2006
7077835	Reconstituting device for injectable medication A device for reconstituting liquid for medical use by bringing together a first liquid medium contained in a first vessel in the form of a cartridge (3) and a second medium, such as a drug in solid form, contained in a second vessel in the form of a vial (...	07/18/2006
7078236	Methods of inducing ovulation The present invention relates to methods of inducing ovulation in a female host comprising the administration of a non-polypeptide cyclic adenosine monophosphate (cAMP) level modulator to the female host. In another aspect, the invention provides for specific admini...	07/18/2006
7053054	Purified LH A process for the purification of recombinant human Luteinizing Hormone (LH) from a sample of crude recombinant LH in the supernatant of CHO cells comprises the combined use of the ion-exchange chromatography and reverse phase HPLC. The ion-exchange chromatography a...	05/30/2006
7053228	Sulfur analogues of 21-hydroxy-6,19-oxidoprogesterone (21OH-6OP) for treating excess of glucocorticoids The present invention is related to novel 21-hydroxy-6,19-oxidoprogesterone (21OH-6OP) analogues, their use as antiglucocorticoids for the treatment and/or prophylaxis of disease associated to an excess of glucocorticoids. In particular, the invention relates to the...	05/30/2006
7018988	Pharmaceutically active pyrrolidine derivatives as Bax inhibitors The present invention is related to new substituted pyrrolidine derivatives of formula (I). Said compounds are preferably for use as pharmaceutically active compounds. Specifically, pyrrolidine derivatives of formula (I) are useful in the treatment and/or prevention...	03/28/2006
7012060	TNF receptor and steroid hormone in a combined therapy The present invention relates to the use of a TNF Receptor together with a steroid hormone to produce a pharmaceutical composition for the treatment of lethal bacterial and viral infections as well as autoimmune and inflammatory diseases. It also relates to said pha...	03/14/2006
6996474	Automated method for identifying related biomolecular sequences The invention relate to an automated method for identifying related biomolecular sequences having defined features of interest from databases, the databases comprising at least a first and a second set of sequences, each set being derived from a different type of or...	02/07/2006
6991938	Method of assay A kinetic assay method for quantifying an analyte in a sample. ...	01/31/2006
6977071	Amino-terminally truncated RANTES as chemokine antagonists The present invention relates to amino-terminally truncated RANTES, lacking NH2-terminal amino acids corresponding to amino acid residues 1, 1-2, 1-3 or 1-4 of the naturally-occurring RANTES and having chemokine antagonistic activity, as well as cDNA sequ...	12/20/2005
6962925	Benzo(C)quinolizine derivatives and their use as 5α-reductases inhibitors A fully and partially reduced benzo(c)quinolizine compound of formula (1): ...	11/08/2005
6905676	Amino-terminally truncated MCP-2 as chemokine antagonists The present invention relates to amino-terminally truncated MCP-2, lacking NH2-terminal amino acids corresponding to amino acid residues 1, 1-2, 1-3, 1-4 or 1-5 of the naturally-occurring MCP-2 and having chemokine antagonistic activity, as well as cDNA s...	06/14/2005
6902728	Chemokine receptor antagonist and cyclosporin in combined therapy The use of a chemokine receptor antagonist together with a cyclosporin to produce a pharmaceutical composition for treating or preventing rejection of transplanted organs, tissues or cells is herein disclosed. Said pharmaceutical compositions for the simultaneous, s...	06/07/2005
6869932	Site-specific preparation of polyethlene glycol-GRF conjugates A method is described for the site-specific preparation of hGRF-PEG conjugates containing one or more PEG units (per mole of hGRF) covalently bound to Lys12 and/or Lys21 and/or Nα, characterized in that the conjugation reaction betw...	03/22/2005
6855684	Compound B as angiogenic agent in combination with human growth factors The present invention refers to the use of Compound B as angiogenic agent in combination with human growth factors. ...	02/15/2005
6852314	IFN-β liquid formulations Interferon-β liquid formulations stabilized with a polyol, a non-reducing sugar or an amino acid. In particular, the formulations are stabilized with a polyol, such as mannitol. The formulations, preferably, furthermore comprise a buffer, such as acetate buffer, at...	02/08/2005
6849720	Monoclonal antibodies to the human LDL receptor, their production and use There are provided monoclonal antibodies to the LDL receptor which are useful for the identification and purification of LDL and in treatment of e.g. hepatitis C infection. ...	02/01/2005
6838433	IL-6 antagonist peptides The present invention relates to IL-6 antagonist peptides, isolatable from a peptide library through the two-hybrids system by their ability to bind to the intracellular domain of gp130 and containing at least 5 amino acids. In particular, such peptides comprise the...	01/04/2005
6770656	Amine derivatives for the treatment of apoptosis The present invention is related to substituted amine derivatives notably for use as pharmaceutically active compounds, as well as to pharmaceutical formulations containing such amine derivatives of formula (I). Said substituted amine derivatives are efficient modul...	08/03/2004
6723850	Process for the synthesis of (1-H)-benzo[c]quinolizin-3-ones derivatives The present invention refers to a process for the preparation of (1H)-benzo[c]quinolizin-3-ones derivatives of general formula (I) which involves only three steps and the use, as starting products, of commercially available, or easily preparable, compounds. The comp...	04/20/2004
6696063	Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy Pathological regional adipose tissue accumulation associated with HIV-associated dysmorphic/dysmetabolic syndrome (HADDS) which may occur with or without subcutaneous adipose tissue lipodystrophy (and which is also described as HIV-associated adipose redi...	02/24/2004
6663867	Hybrid heterodimeric protein hormone comprising a TNF binding protein and a glycoprotein hormone subunit and method of using same A hybrid protein includes two coexpressed amino acid sequences forming a dimer. Each sequence contains the binding portion of a receptor, such as TBP1 or TBP2, or a ligand, such as IL-6, IFN-ଲ and TPO, linked to a subunit of a heterodimeric proteina...	12/16/2003
6663865	Tumor necrosis factor antagonists and their use in endometriosis Tumor necrosis factor antagonists are administered in therapeutically effective doses to treat and/or prevent endometriosis. The antagonists of this invention typically are selected from among several classes but preferably are soluble TNF receptors. The ...	12/16/2003
6660848	Allelic variant of human STAT3 A predominant allelic variant of the human STAT3 protein, the cDNA sequence encoding it, its use in therapy and/or in diagnosis of autoimmune and/or inflammatory diseases, as well as pharmaceutical compositions comprising it....	12/09/2003
6645171	Reconstituting device for injectable medication A device for reconstituting liquid for medical use by bringing together a first liquid medium contained in a first vessel in the form of a cartridge (3) and a second medium, such as a drug in solid form, contained in a second vessel in the form of a vial ...	11/11/2003

«First «Previous1 2 3 Next»Last»

PatentStorm

Quotables

PatentStorm News

Assignee: Applied Research Systems ARS Holding N.V.